Hong Kong Pharma Digital Technology (NASDAQ:HKPD) Releases Earnings Results

Hong Kong Pharma Digital Technology (NASDAQ:HKPD) released its earnings results on Friday. The company reported ($0.04) earnings per share (EPS) for the quarter, FiscalAI reports. The firm had revenue of $3.15 million during the quarter.

Hong Kong Pharma Digital Technology Stock Performance

HKPD stock opened at $0.42 on Friday. The firm has a 50 day simple moving average of $0.42 and a 200 day simple moving average of $0.58. Hong Kong Pharma Digital Technology has a 52 week low of $0.31 and a 52 week high of $2.58.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d)” rating on shares of Hong Kong Pharma Digital Technology in a research report on Wednesday, July 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.

Institutional Investors Weigh In On Hong Kong Pharma Digital Technology

An institutional investor recently bought a new position in Hong Kong Pharma Digital Technology stock. StoneX Group Inc. bought a new stake in shares of Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 43,284 shares of the company’s stock, valued at approximately $36,000. StoneX Group Inc. owned 0.39% of Hong Kong Pharma Digital Technology as of its most recent SEC filing.

About Hong Kong Pharma Digital Technology

Hong Kong Pharma is an exempted limited liability company formed under the laws of the Cayman Islands on August 17, 2023. As a holding company with no material operations of its own, Hong Kong Pharma conducts its operations through its wholly owned subsidiaries, Joint Cross Border Logistics Company Limited and V-Alliance Technology Supplies Limited, each a limited liability corporation incorporated in Hong Kong and collectively referred to as HK Subsidiaries. Our business offering consists of two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, primarily conducted through our Hong Kong subsidiary, Joint Cross Border, which we refer to as the “Supply Chain Services” division and (ii) OTC pharmaceutical cross-border procurement and distribution, primarily conducted through our Hong Kong subsidiary, V-Alliance, which we refer to as the “Procurement and Distribution” division.